Molecular subtyping can help predict outcomes and chemotherapy benefit in patients with colorectal cancer, according to a presentation at the annual conference of the American Society of Clinical Oncology (ASCO).
MET protein levels correlate strongly with epithelial-mesenchymal transition (EMT) phenotype, a treatment-resistant type of colorectal cancer and may be used as a surrogate biomarker, according to new research from The University of Texas MD Anderson Cancer Center.
Study Examines Effects of Lipid-Lowering Medicines on Cancer Patients Treated for High Cholesterol, Diabetes and Heart Disease
Smartphones and tablets can make for sleep-disrupting bedfellows. One cause is believed to be the bright light-emitting diodes that allow the use of mobile devices in dimly lit rooms; the light exposure can interfere with melatonin, a hormone that helps control the natural sleep-wake cycle. But there may be a way to check your mobile device in bed and still get a good night’s sleep. A Mayo Clinic study suggests dimming the smartphone or tablet brightness settings and holding the device at least 14 inches from your face while using it will reduce its potential to interfere with melatonin and impede sleep.
Cancer immunotherapy is showing promise in treating patients with a variety of advanced, metastatic tumors, as evidenced by two newly unveiled studies from Yale Cancer Center.
Eighty-three percent of cancer doctors report that they’ve faced oncology drug shortages, and of those, nearly all say that their patients’ treatment has been impacted, according to a study from researchers at the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania that will be presented today at the 2013 annual meeting of the American Society of Clinical Oncology (Abstract #CRA6510). The results showed that shortages – which have hit especially hard among drugs to treat pediatric, gastrointestinal and blood cancers – have left physicians surveyed unable to prescribe standard chemotherapies for a range of cancers.
A team of researchers led by Jedd Wolchok of the Ludwig Center at MSKCC presented data today at the ASCO Annual Meeting showing promising results from a Phase I clinical trial evaluating the concurrent use of two immunotherapies for the treatment of advanced melanoma.
Patients with cancer that has spread to their bones are often treated with radiation therapy to reduce pain. But if that treatment doesn’t work, or can’t be used again, a second, effective option now exists. Results of a clinical trial on the new therapy, presented by a researcher at Jefferson’s Kimmel Cancer Center, is being presented at the annual meeting of the American Society of Clinical Oncology (ASCO).
The HER2 growth-factor gene is known to be over-active in breast and gastro-esophageal cancers. But now, irregularities in the genes ‘s expression — among them mutations, amplifications, substitutions, and translocations — have been found in 14 different advanced solid tumors.
Adding bevacizumab (Avastin) to standard chemotherapy and radiation treatment does not improve survival for patients newly diagnosed with glioblastoma, a very aggressive form of brain cancer, researchers have found. The results of the large, multicenter study are being presented today at the American Society of Clinical Oncology (ASCO) annual meeting.
Even though a majority of U.S. oncologists report satisfaction with their careers, many say they have experienced at least one symptom of burnout, a Mayo Clinic-led study has found. The study was released during the American Society of Clinical Oncology’s annual meeting in Chicago.
The kidney and liver cancer drug sorafenib holds metastatic thyroid cancer at bay for nearly twice as long as a placebo, according to results of a randomized phase III trial, which will be presented today by a researcher from the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania in a plenary session during the American Society of Clinical Oncology’s annual meeting (Abstract #4).
A Radiation Therapy Oncology Group trial found that adding bevacizumab to initial treatment for glioblastoma did not improve patient overall survival or progression-free survival,. Results were reported June 2 at the plenary session of the American Society of Clinical Oncology 2013 Annual Meeting.
Gene panel may help personalize therapy for aggressive brain tumors.
The angiogenesis inhibitor bevacizumab (Avastin) failed to increase overall survival (OS) or statistically significant progression-free survival (PFS) for glioblastoma patients in the frontline setting, according to research led by researchers at The University of Texas MD Anderson Cancer Center.
The experimental drug selumetinib is the first targeted therapy to demonstrate significant clinical benefit for patients with metastatic uveal melanoma, according to new Memorial Sloan-Kettering Cancer Center research presented on Saturday, June 1, at the 49th annual meeting of the American Society of Clinical Oncology (ASCO).
Spouses and long-term partners of patients with mouth and throat cancers related to infection with the human papilloma virus (HPV) appear to have no increased prevalence of oral HPV infections, according to results of a multicenter, pilot study led by Johns Hopkins investigators. The study’s results suggest that long-term couples need not change their sexual practices, say the scientists.
Many glioblastoma patients treated with bevacizumab (Avastin®) have significant deterioration in neurocognitive function, symptoms and quality of life.
Peripheral arterial disease is a common circulation problem in which reduced blood flow can lead to complications that jeopardize the limbs, possibly even requiring amputation. Procedures known as revascularization have reduced the need for amputations 40 percent over two decades, Mayo Clinic research shows.
In a randomized phase III clinical trial conducted by the Radiation Therapy Oncology Group (RTOG), high-dose (HD), compared with standard-dose (SD), radiotherapy (RT) with concurrent chemotherapy (CT) did not improve overall survival of patients with stage III non-small-cell lung cancer (NSCLC).
The latest research discoveries on diabetes, obesity, endocrine-disrupting chemicals, adolescent health and clinical trials will be highlighted in a series of press conferences at ENDO 2013: The 95th Annual Meeting & Expo of The Endocrine Society.
The first symptoms of major depression may be behavioral, but the common mental illness is based in biology — and not limited to the brain.
Two traumatic brain-injury patients steadily emerged from minimally conscious state after receiving intrathecal baclofen therapy under the care of neurosurgeons at Evangelismos Hospital in Athens.
Young athletes who specialize in one sport and train intensively have a significantly higher risk of stress fractures and other severe overuse injuries, according to the largest clinical study of its kind.
People with rheumatic diseases don’t take their medication on a regular basis, and this leads to poor outcomes in their disease treatment, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.
Chronic lower back pain may be linked to a recently defined form of inflammatory arthritis known as axial spondyloarthritis, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.
Millions suffer from musculoskeletal injuries and conditions.
Data shows that when over-the-counter (OTC) naproxen sodium, commercially sold as Aleve, was added to an aspirin therapy regimen, there was no change in platelet aggregation measures versus baseline. Unlike ibuprofen, which can negate the intended cardiovascular benefit of aspirin therapy, an OTC dose of naproxen sodium did not change the antiplatelet effect profile seen with aspirin therapy alone.
According to a new survey released this week in conjunction with the National MS Society's National Conference, many people living with multiple sclerosis (MS) who experience visual, dexterity, and cognitive challenges report that technology plays a vital role in helping them live with the disease. However, relatively few are using the assistive technologies that could help them overcome many of these challenges.
Complementary or alternative medicine (CAM) has increased tremendously in popularity in the United States, and one of the most common reasons that patients turn to CAM is for treating allergic diseases according to information presented at the allergists' annual meeting. Experts study the role of CAM treatments including traditional Chinese medicine and probiotics.
While no one knows the precise underlying cause leading to Alzheimer's disease, a new study finds that a "leaky" blood-brain barrier (BBB) "” and levels of water-soluble antioxidants "” may offer clues to unlocking this haunting disease.
Dozens of medical research experts will assemble Feb. 23-25, 2006, in Chantilly, Va., to discuss how patient-reported outcomes (PROs) should be developed, validated, interpreted and used in clinical trials.
People with excessive sweating disorder find Botox injections can improve their quality of life.
A new research study examines the relationship between the presence of frontal pain and CRS disease process, and the association between frontal pain and degree of frontal sinus disease as determined by CT scan.
Experts still debate treatment for the frontal sinuses; how to effectively deal with surgery, medical management, and surgical failures. A new study set out to document the causes of those failures in patients who had undergone surgical treatment for sinus disorders.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right